Trial Profile

First-in-Human, Phase 1 Study of AMT-116 in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMT 116 Multitude Therapeutics (Primary)
Indications Advanced breast cancer; Basal cell cancer; Biliary cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Large cell carcinoma; Liver cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Skin cancer; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors Multitude Therapeutics

Most Recent Events

23 Oct 2024 Planned number of patients changed from 48 to 80.
04 Jun 2024 Results ( As of Feb 1, 2024, n=8) assessing safety of AMT-116 in patients with advanced solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
24 Jul 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com